| 40 |
Kitano Y, Okabe H, Yamashita YI, et al. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma [J]. Br J Cancer, 2018, 118(2): 171-180.
|
| 41 |
Gani F, Nagarajan N, Kim Y, et al.Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma [J]. Ann Surg Oncol, 2016, 23(8): 2610-2617.
|
| 42 |
Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer [J]. Nat Genet, 2015, 47(9): 1003-1010.
|
| 43 |
Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency [J]. Chin Clin Oncol, 2016, 5(5): 62.
|
| 44 |
Bang YJ, Doi T, De Braud F, et al. Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028 [J]. Eur J Cancer, 2015, 51: S112.
|
| 45 |
Le DT, Durham JN, Smith KN, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [J]. Science, 2017, 357(6349): 409-413.
|
| 46 |
Czink E, Kloor M, Goeppert B, et al. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer [J]. Cold Spring Harb Mol Case Stud, 2017, 3(5). pii: a001974.
|
| 47 |
Kelley RK, Mitchell E, Behr S, et al.Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): clinical outcomes and biomarker analyses [J]. J Clin Oncol, 2018, 36(15_suppl): 4087.
|
| 48 |
Recchia F, Sica G, Candeloro G, et al. Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study [J]. Pancreas, 2009, 38(6): e163-e168.
|
| 49 |
Seto K, Shoda J, Horibe T, et al. Targeting interleukin-4 receptor alpha by hybrid peptide for novel biliary tract cancer therapy [J]. Int J Hepatol, 2014, 2014: 584650.
|
| 50 |
Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4＋ T cells in a patient with epithelial cancer [J]. Science, 2014, 344(6184): 641-645.
|
| 51 |
Feng KC, Guo YL, Liu Y, et al. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma [J]. J Hematol Oncol, 2017, 10(1): 4.
|
| 52 |
Yoshitomi M, Yutani S, Matsueda S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis [J]. Exp Ther Med, 2012, 3(3): 463-469.
|
| 53 |
Shirahama T, Muroya D, Matsueda S, et al. A randomized phaseⅡ trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer [J]. Cancer Sci, 2017, 108(5): 838-845.
|
| 54 |
Kobayashi M, Sakabe T, Abe H, et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer [J]. J Gastrointest Surg, 2013, 17(9): 1609-1617.
|
| 1 |
Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma [J]. Best Pract Res Clin Gastroenterol, 2015, 29(2): 221-232.
|
| 2 |
Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma [J]. Hepatology, 2011, 54(1): 173-184.
|
| 3 |
Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].Ann Oncol, 2016, 27(suppl 5): v28-v37.
|
| 4 |
Høgdall D, O′Rourke CJ, Taranta A, et al.Molecular pathogenesis and current therapy in intrahepatic cholangiocarcinoma [J]. Dig Dis, 2016, 34(4): 440-451.
|
| 5 |
Valle J, Wasan H, Palmer DH, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer [J]. N Engl J Med, 2010, 362(14): 1273-1281.
|
| 6 |
Glimelius B, Hoffman K, Sjödén PO, et al.Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer [J]. Ann Oncol, 1996, 7(6): 593-600.
|
| 7 |
Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan [J]. Br J Cancer, 2010, 103(4): 469-474.
|
| 8 |
Valle JW, Furuse J, Jitlal M, et al.Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials [J]. Ann Oncol, 2014, 25(2): 391-398.
|
| 9 |
Mizusawa J, Morizane C, Okusaka T, et al.Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT) [J].Jpn J Clin Oncol, 2016, 46(4): 385-388.
|
| 10 |
Fiteni F, Nguyen T, Vernerey D, et al. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review [J]. Cancer Med, 2014, 3(6): 1502-1511.
|
| 11 |
Gelibter A, Malaguti P, Di Cosimo S, et al. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree [J]. Cancer, 2005, 104(6): 1237-1245.
|
| 12 |
Williams KJ, Picus J, Trinkhaus K, et al. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study [J]. HPB (Oxford), 2010, 12(6): 418-426.
|
| 13 |
Iqbal S, Rankin C, Lenz HJ, et al. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202 [J]. Cancer Chemother Pharmacol, 2011, 68(6): 1595-1602.
|
| 14 |
Kornek GV, Schuell B, Laengle F, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phaseⅡ trial [J]. Ann Oncol, 2004, 15(3): 478-483.
|
| 15 |
Ridwelski K, Fahlke J, Kuhn R, et al. Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma [J]. Eur J Surg Oncol, 2006, 32(3): 297-302.
|
| 16 |
Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial [J]. Cancer, 2005, 103(1): 111-118.
|
| 17 |
Ducreux M, Van Cutsem E, Van Laethem JL, et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial [J]. Eur J Cancer, 2005, 41(3): 398-403.
|
| 18 |
Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phaseⅡ trial [J]. Br J Cancer, 2008, 98(2): 309-315.
|
| 19 |
Kim TW, Chang HM, Kang HJ, et al. PhaseⅡ study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer [J]. Ann Oncol, 2003, 14(7): 1115-1120.
|
| 20 |
Shroff RT, Javle MM, Xiao LC, et al. A phase II trial of gemcitabine (G), cisplatin (C), and nab-paclitaxel (N) in advanced biliary tract cancers (aBTCs): tpdated survival analysis [J]. J Clin Oncol, 2018, 36(4_suppl): 350.
|
| 21 |
Lamarca A, Hubner RA, David Ryder W, et al. Second-line chemotherapy in advanced biliary cancer: a systematic review [J]. Ann Oncol, 2014, 25(12): 2328-2338.
|
| 22 |
Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study [J]. Lancet Oncol, 2012, 13(2): 181-188.
|
| 23 |
Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial [J]. Lancet Oncol, 2014, 15(8): 819-828.
|
| 24 |
Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study) [J]. Cancer, 2016, 122(4): 574-581.
|
| 25 |
Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study [J]. Lancet Oncol, 2010, 11(1): 48-54.
|
| 26 |
Iyer RV, Pokuri VK, Groman A, et al. A multicenter phaseⅡ study of gemcitabine, capecitabine, and bevacizumab for locally advanced or metastatic biliary tract cancer [J].Am J Clin Oncol, 2018, 41(7): 649-655.
|
| 27 |
Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phaseⅡ consortium study [J]. J Clin Oncol, 2010, 28(21): 3491-3497.
|
| 28 |
Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial [J]. Lancet Oncol, 2015, 16(8): 967-978.
|
| 29 |
Sun W, Patel A, Normolle D, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary adenocarcinoma [J]. Cancer, Epub 2018 Dec 18.
|
| 30 |
Peck J, Wei L, Zalupski M, et al. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib [J]. Oncology, 2012, 82(3): 175-179.
|
| 31 |
Kwak EL, Shapiro GI, Cohen SM, et al. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation [J]. Cancer, 2013, 119(16): 3043-3051.
|
| 32 |
Yamashita- Kashima, Fujimura T, Shu S. Preclinical study of antitumor activity of trastuzumab emtansine in HER2-positive biliary tract cancer[C]. ASCO-GI abstract 256, 2018.
|
| 33 |
Milind MJ, John DH, Charles S, et al. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from MyPathway [J]. J Clin Oncol, 2017, 35(4_supp1): 402.
|
| 34 |
Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phaseⅡ study of selumetinib in patients with metastatic biliary cancers [J]. J Clin Oncol, 2011, 29(17): 2357-2363.
|
| 35 |
Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management [J]. Cancer, 2016, 122(24): 3838-3847.
|
| 36 |
Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma [J]. J Clin Oncol, 2018, 36(3): 276-282.
|
| 37 |
M L, G AA, B H. Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts [J]. J Clin Oncol, 2017, 35: 4015.
|
| 38 |
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment [J]. Cancer Cell, 2012, 21(3): 309-322.
|
| 39 |
Wang Y, Ding M, Zhang Q, et al. Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis [J]. J Cancer, 2017, 8(1): 74-84.
|